MED
Medifast, Inc.
Set alert
12.15 USD -0.11 -0.90%
12.00 Day range 12.48
9.45 52-week range 13.15
- YTD
- +13.76%
- 1 year
- +0.08%
- Open
- 12.24
- Prev close
- 12.26
- Mkt cap
- 135.87M
- Vol
- 231.90K
- Avg vol
- 141.63K
- EPS
- -3.70
- P/E
- 0.00
- Div yield
- 34.41%
More statistics
- Low
- 12.00
- High
- 12.48
- Forward P/E
- 56.17
- Beta
- 1.16
- Short ratio
- 7.68
- Inst. own
- 86.16%
- Dividend
- 6.60
- Ex-div date
- Sep 17, 2023
- 50-d avg
- 18.72
- 200-d avg
- 22.71
- 1y target
- 16.50
Key statistics
- Market cap
- 184.30M
- Enterprise value
- 27.90M
- Trailing P/E
- 25.15
- Forward P/E
- 56.17
- PEG ratio
- 0.00
- Price / sales
- 0.27
- Price / book
- 0.87
- EPS (TTM)
- 0.67
- Beta
- 1.16
- Dividend yield
- 34.41%
- Payout ratio
- 0.00%
- Profit margin
- 1.09%
- Revenue (TTM)
- 674.48M
- Revenue growth
- -40.60%
- Free cash flow
- -7.09M
- Total cash
- 169.96M
- Total debt
- 17.63M
- Return on equity
- 3.66%
- Shares outstanding
- 10.94M
- Short % of float
- 22.52%
- 50-day average
- 18.72
- 200-day average
- 22.71
Analyst view
Consensus: none
Price target (mean) 16.50 +35.8% upside
Now 12.15
- Target (low)
- 16.00
- Target (mean)
- 16.50
- Target (high)
- 17.00
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Financials — quick view
MED Revenue — quarterly 72.05M
MED Net income — quarterly -17.51M
MED EPS — quarterly -1.57
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.15 | 0.35 | +0.50 | +333.33% |
| Aug 5, 2024 | Jun 1, 2024 | 0.36 | 0.92 | +0.56 | +155.56% |
| Apr 29, 2024 | Mar 1, 2024 | 0.78 | 0.66 | -0.12 | -15.38% |
| Feb 20, 2024 | Dec 1, 2023 | 0.99 | 1.09 | +0.10 | +10.10% |
| Nov 6, 2023 | Sep 1, 2023 | 1.02 | 2.12 | +1.10 | +107.84% |
| Aug 7, 2023 | Jun 1, 2023 | 1.44 | 2.77 | +1.33 | +92.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2024 | DA Davidson | up | Underperform | Neutral |
| Jul 22, 2024 | DA Davidson | main | Underperform | Underperform |
| Jun 5, 2024 | DA Davidson | down | Neutral | Underperform |
| Apr 30, 2024 | DA Davidson | main | Neutral | Neutral |
| Feb 21, 2024 | DA Davidson | main | Neutral | Neutral |
| Oct 13, 2023 | Stephens & Co. | init | — | Equal-Weight |
About Medifast, Inc.
Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
- Sector
- Consumer Cyclical
- Industry
- Personal Services
- Country
- United States
- Website
- medifastinc.com
News
- Medifast Is Running The Same Playbook, And I Have The Same Concerns
- Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises
- Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
- What Medifast (MED) Said on Its Q3 Earnings Call
- Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates
- Medifast Q3 2026 Earnings Call Transcript
- Medifast Lowers FY2026 GAAP EPS Guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) Est
- Medifast Sees FY2026 Adj EPS $(0.70)-$(0.45) vs $(0.94) Est; Raises FY2026 Sales Guidance from $270.000M-$300.000M to $280.000M-$300.000M vs $287.700M Est
- Medifast Q3 Adj. EPS $(0.19) Beats $(0.35) Estimate, Sales $72.048M Beat $71.300M Estimate
- Medifast Sees Q4 GAAP EPS $0.00-$0.25 vs $(0.12) Est; Sees Sales $55.000M-$75.000M vs $64.100M Est
Your note
Sign in to keep a note on MED — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN JEFFREY J. | Director | Stock Award(Grant) | Jun 19, 2024 | 22,193 |
| CHARD DANIEL R | Chief Executive Officer | Stock Award(Grant) | Mar 12, 2024 | 211,828 |
| GEARY ELIZABETH A. | Director | Stock Award(Grant) | Jun 19, 2024 | 8,377 |
| HALLQUIST CONSTANCE J | Former | Sale | Oct 5, 2023 | 0 |
| HOER MICHAEL A. | Director | Stock Award(Grant) | Jun 19, 2024 | 14,971 |
| MACKENZIE JONATHAN BARRETT | Officer | Stock Award(Grant) | Mar 12, 2024 | 4,051 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 9.20% | 1,006,210 | 16.95M | Sep 29, 2024 |
| Blackrock Inc. | 8.01% | 876,114 | 14.76M | Sep 29, 2024 |
| Vanguard Group Inc | 6.64% | 726,167 | 12.24M | Sep 29, 2024 |
| AQR Capital Management, LLC | 3.52% | 384,598 | 6.48M | Sep 29, 2024 |
| Morgan Stanley | 2.93% | 321,007 | 5.41M | Sep 29, 2024 |
| Bank of America Corporation | 2.88% | 314,728 | 5.30M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.26% | 356,866 | 6.01M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.68% | 292,768 | 4.93M | Oct 30, 2024 |
| Avantis U.S. Small Cap Value ETF | 1.84% | 201,586 | 3.40M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.48% | 162,005 | 2.73M | Sep 29, 2024 |
| Vanguard Consumer Staples Index Fund | 1.17% | 127,545 | 2.15M | Aug 30, 2024 |
| Federated Hermes MDT Small Cap Core Fund | 1.15% | 125,563 | 2.12M | Jul 30, 2024 |